Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer

DISEASE CHARACTERISTICS:

• Diagnosis of differentiated thyroid cancer

  • Locoregionally extensive and/or metastatic disease
  • Inoperable disease
• Failed prior conventional therapy that included total/near-total thyroidectomy AND radioactive iodine I 131 ablation therapy

• Elevated thyroglobulin (Tg) levels (> 3 ng/mL on thyroid hormone OR > 10 ng/mL off thyroid hormone)

  • Tg-antibody positive patients are eligible despite the Tg level

• Radioactive iodine (RAI) scan showing no or therapeutically insignificant (< 1%) RAI uptake after thyroid hormone withdrawal

  • Scan performed within the past 18 months

PATIENT CHARACTERISTICS:

Age

• 18 and over

Performance status

• Not specified

Life expectancy

• Not specified

Hematopoietic

• Hemoglobin ≥ 10 g/dL
• WBC ≥ 3,000/mm^3
• Platelet count ≥ 50,000/mm^3

Hepatic

• ALT ≤ 2 times upper limit of normal

Renal

• Creatinine ≤ 1.5 mg/dL

Cardiovascular

• No New York Heart Association class III or IV cardiac disease

Other

• Not pregnant
• No nursing within the past 3 months
• Negative pregnancy test
• Fertile patients must use effective contraception
• No allergy to thiazolidinediones
• No other malignancy except basal cell skin cancer

PRIOR CONCURRENT THERAPY:

Biologic therapy

• Not specified

Chemotherapy

• More than 3 months since prior chemotherapy

Endocrine therapy

• See Disease Characteristics
• No concurrent levothyroxine

Radiotherapy

• See Disease Characteristics
• No prior cumulative dose of radioiodine ≥ 800 mCi
• Prior adjuvant or therapeutic external beam radiotherapy allowed

Surgery

• See Disease Characteristics